Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
Calphalon, a leader in premium cookware, announces the launch of its latest innovation, Calphalon Premier™ Space Saving Nonstick and Stainless Steel Cookware, which stacks securely to save 30% more space* in the kitchen. With a unique handle design and flat glass covers, the pots, pans and lids can stack and nest in any order**, allowing both professional and home cooks to save valuable cabinet space. Both nonstick and stainless steel lines deliver exceptional cooking results, while providing consumers with a breakthrough solution that keeps their kitchen organized.
“Through our research, we found that the average size of the American home is shrinking, and that many consumers have limited space in their kitchen to store cookware,***” said Tim Anderson, Director of Brand Development, Calphalon. “Calphalon Premier™ Space Saving Cookware provides home cooks with 30% more space in their cabinets,* helping to declutter their kitchen so they can focus on what matters – creating a great meal for family and friends.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8177251-calphalon-premier-nonstick-stainless-steel-cookware/
St. Jude Children’s Research Hospital® officials and guests today marked the opening of the St. Jude Red Frog Events Proton Therapy Center, the first proton therapy center in the world dedicated solely to children with cancer.
Patients are now being treated at the center using precisely delivered, high-energy particles called protons to kill or shrink tumors while minimizing damage to healthy tissue and organs. For patients with brain tumors and certain other cancers, research suggests proton beam therapy may be more effective than conventional radiation at preventing the growth and spread of tumors while reducing the risk of treatment-related side effects.
To view the multimedia release go to:
http://www.multivu.com/players/English/7713451-st-jude-proton-therapy-opening/
TriggerPoint™, the market leader in foam rolling, movement products and education, today announces the launch of the GRID VIBE premium vibrating foam roller. Designed for muscle relaxation and pain reduction, the GRID VIBE pairs TriggerPoint’s patented GRID foam roller design with vibration technology to deliver enhanced muscle mobility experiences.
The GRID VIBE’s vibration frequency is specifically calibrated at 33 hertz for optimal muscle relaxation, minimizing discomfort and allowing users to focus longer on foam rolling tender areas. Research shows that vibration decreases the body’s sensation of pain. When vibration is paired with TriggerPoint’s signature GRID pattern that mimics a massage therapist’s hands, fingers and fingertips, the GRID VIBE effectively targets more layers of tight muscle tissue. The GRID VIBE can be used by anyone for muscle recovery, injury prevention, improving athletic performance, pain management, or boosting overall body movement and mobility.
To view the multimedia release go to:
https://www.multivu.com/players/English/8135751-triggerpoint-grid-vibe-vibrating-foam-roller/
St. Jude Children’s Research Hospital is naming the institution’s principal research tower after Donald Pinkel, M.D., whose legacy of driving progress toward advancing cures for pediatric catastrophic diseases continues at the institution today.
When St. Jude was established 55 years ago, Pinkel, the hospital’s first medical director, committed to finding cures for childhood cancer, leading to groundbreaking treatments that saved countless children’s lives. Many of these cancers were deemed incurable prior to Pinkel’s research, but his distinct approach to eradicating diseases established a model for how cancers could be treated.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924752-st-jude-childrens-research-hospital-donald-pinkel-tower/
Research from CEB (NYSE: CEB), a best practice insight and technology company and the creators of the Challenger™ Selling model, shows that 51 percent of customers who might be willing to buy from a supplier are not willing to advocate for them and help them get deals over the finish line. This is a direct result of the difficult, internal buying process. Unfortunately, sales organizations lack a true understanding of their customers and are unable to simplify the complexities of buying for them.
“Willingness to buy is not the same as willingness to advocate; suppliers need customers to advocate and fight for them to get deals done today,” said Brent Adamson, principal executive advisor at CEB and co-author of The Challenger Sale and The Challenger Customer. “In order to move past ‘good enough’ and ‘status quo,’ suppliers need to go beyond just understanding how customers interact with them, to gaining a thorough understanding of how they work, what is important to them and how they interact with each other.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7427254-ceb-challenge-align-prescribe-b2b-sales-strategy/
This year, parents of nearly 16,000 children in the U.S. will hear the words: “Your child has cancer.” One in five of those children won’t survive. September is Childhood Cancer Awareness Month, and as a leader in the way the world understands, treats and defeats childhood cancer and other life-threatening diseases, St. Jude Children’s Research Hospital® will focus on raising awareness and funds for this very important issue.
Despite significant progress made by St. Jude Children’s Research Hospital, which has helped push the overall childhood cancer survival rates from 20 to more than 80 percent since the hospital opened in 1962, cancer remains the leading cause of death by disease for children over the age of 1. Each year about 175,000 children are diagnosed with cancer worldwide, and 60 percent of these kids don’t have access to modern treatment. For those who win their battles against childhood cancer, victory often comes at a cost as survivors face a much higher risk of experiencing unique long-term health effects later in life.
To view the multimedia release go to:
http://www.multivu.com/players/English/7390851-st-jude-hospital-childhood-cancer-awareness/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
An international coalition of cities is calling for an ambitious global goal to prevent more than 100 million new cases of diabetes by 2045. The target is set out alongside new research in a report launched today by the Cities Changing Diabetes partnership at a global summit in Houston, Texas. The report comes with the stark warning that achieving the goal requires cutting rates of obesity by a quarter.
To view the multimedia release go to:
https://www.multivu.com/players/English/8202451-cities-changing-diabetes-global-obesity-rates/
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
In this video shanthala Avigna clinical research student talking about teaching, placement and excellent facility provided to students in all aspects to reach their goal.
The Level 3 Threat Research Labs, Level 3 Communications' (LVLT) threat intelligence and research arm, unveiled new research about the botnet size and behavior for the malware commonly referred to as Lizkebab, BASHLITE, Torlus or gafgyt, including botnet size and victim stats.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911451-level-3-threat-research-malware/
